Richard Socher

You just had to scale the existing ideas and modify them around the edges and improve them here and there.

And then I just love all these use cases and, you know, especially some deep industries like healthcare.

It was clear that I needed support and help from people who deeply know the space, know how pharma companies actually develop and bring new medications and cures into the market and drugs.

But, you know, every single space has space.

has this opportunity right now in AI.

Like AI will change every industry.

That's why it's sort of AI of X, you know, like, and then oftentimes you can think from first principles, sort of what would people really want, like in that industry?

And can you make that now possible with AI?

So we wanted to

connect some of the world's leading experts like Chris Manning and Steve Goldblum with really strong industry experts like Nick Kranz and our team or Krish and actually merge them.

And that's what allowed us to invest in these really exciting companies.

I'll just give you one example.

One is called ParallelBio.

They build organoids and with AI, they are able to track the organoids and see how they are influenced by different... Like little collections of kidney cells.

Exactly.

In their case, they build lymph nodes, lymph node organoids.

And so this one company actually got FDA approval to skip for toxicity testing of immune systems, animal trials.

by using these organoids in a petri dish being evaluated and created partially by AI and robotic processes.

And so it's an incredibly exciting company that single-handedly could, at scale, save millions of animal lives.

And so when I hear all these people saying, oh, AI, it's so terrible, I'm like,